Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC

NCT06601309 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Serplulimab
DRUG: Paclitaxel+Cisplatin (Neoadjuvant Chemotherapy)
DRUG: Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
RADIATION: Radiotherapy

Sponsor

Fujian Medical University Union Hospital